Claritas Pharmaceuticals Inc V.CLAS.H

Claritas in tight with Salzman Group, gotto wonder why?

[Dude51]

Because both know what there doing.
Point of fact:

From
https://kalyteran.co/index.php?/topic/620-vacations-over-time-to-help-advertise-your-company-folks/&tab=comments#comment-1920

"R 107 will become the gold standard against which other NO drugs are measured against."" ~ Dr Andrew Salzman"

Who is Andrew Salzman?

Andrew Salzman, MD
Scientific Advisor

Dr. Salzman is a physician, scientist, inventor, and biomedical entrepreneur with more than 20 years of experience in biomedical drug discovery and development. He studied psychology and English literature at Yale College and medicine at Harvard Medical School. After a pediatric internship and residency at Columbia University (New York, NY), he undertook  post-doctoral fellowships in pediatric critical care, neonatal critical care, immunology, epithelial biology, and pediatric infectious disease at the Weizmann Institute of Science in (Rehovot, Israel), Children’s Hospital Medical Center (Boston, MA), the Massachusetts General Hospital (Boston, MA), the University of Massachusetts Medical Center (Worcester, MA), and Beth Israel Hospital Medical Center (Brookline, MA). Prior to his entrepreneurial career in biotechnology, he founded and led the Division of Critical Care Medicine at Children’s Hospital Medical Center (Cincinnati, OH), one of the largest pediatric critical care programs in North America.

In 1999, Dr. Salzman left academia to found Inotek Pharmaceuticals, followed by the founding and leadership of a number of biotechnology companies in Israel and the United States, including Radikal Therapeutics, Salzman Capital Ventures, Salzman Lovelace Investments, and Respirometics. Over the past twenty years, Dr. Salzman has received funding for 135 NIH, DARPA, and BARDA grants totaling $160 million. This work has supported research activities resulting in 200 scientific publications and 50 patents, spanning work in ischemia-reperfusion injury, intestinal mucosal biology, pulmonary arterial hypertension, autoimmune disease, and mechanisms of pro-inflammatory gene expression.

His basic scientific discoveries include the identification of:

    the enhancer region of the human inducible nitric oxide synthase gene
    the principal microbial protein (flagellin) that activates inflammation in epithelial cells
    the enzyme in bacteria that detoxifies nitric oxide (flavohemoglobin)
    the first soluble nitric oxide donor that selectively lowers pulmonary hypertension
    the first nitric oxide synthase inhibitor selective for the inducible isoform
    the first ultrapotent selective A1 agonist
    the first nanomolar-potent PARP inhibitor

Now the bashers of this stock will have you believe both Andrew and Robert are idiots.
When you mention phd to them, they think pretty hot dame....lol

[bud13]

or they could be phoney hyped dummies (PhD)

[Glta613]

Do your DD on: Professor Salvatore Cuzzocrea, President of the University of Messina and former President of the European Shock Society, is working with Salzman Group and Claritas, andhas read and approved of the scientificdisclosure in this news release. This guy is as proper as they come and he wouldn't be attaching his name to some bs. The guy's beyond impressive tbh.